{"id":"placebo-fluorouracil-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"}]},"_chembl":{"chemblId":"CHEMBL197201","moleculeType":"Small molecule","molecularWeight":"520.35"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and disrupts DNA/RNA synthesis. Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication and transcription. Together they provide synergistic cytotoxic effects against rapidly dividing cancer cells. The placebo arm allows for comparative efficacy assessment in this phase 3 trial.","oneSentence":"This combination uses fluorouracil and cisplatin chemotherapy agents to inhibit DNA synthesis and induce cancer cell death, with placebo as a control arm in the trial design.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:52.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer (likely indication based on CStone pipeline)"}]},"trialDetails":[{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT04550260","phase":"PHASE3","title":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":640},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT01720563","phase":"PHASE2","title":"A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy","status":"TERMINATED","sponsor":"PhytoHealth Corporation","startDate":"2012-12","conditions":"Cancer-related Fatigue","enrollment":17},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":"Urinary Bladder Neoplasms","enrollment":520},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT03189719","phase":"PHASE3","title":"First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-07-25","conditions":"Esophageal Neoplasms","enrollment":749},{"nctId":"NCT04428333","phase":"PHASE3","title":"Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2020-08-12","conditions":"Neoplasms, Head and Neck","enrollment":117},{"nctId":"NCT06349044","phase":"NA","title":"A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-03-20","conditions":"Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma","enrollment":120},{"nctId":"NCT06241599","phase":"PHASE2, PHASE3","title":"A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":300},{"nctId":"NCT04187352","phase":"PHASE3","title":"A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2019-12-19","conditions":"Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":540},{"nctId":"NCT03748134","phase":"PHASE3","title":"Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-24","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":746},{"nctId":"NCT04297995","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2020-07-29","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":131},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT03958890","phase":"PHASE3","title":"A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-06-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":489},{"nctId":"NCT02494583","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-31","conditions":"Gastric Adenocarcinoma","enrollment":763},{"nctId":"NCT05433597","phase":"PHASE2, PHASE3","title":"A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-01","conditions":"Nasopharyngeal Carcinoma, TNF, Chemo-radiotherapy","enrollment":172},{"nctId":"NCT05213312","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-06-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT04859582","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":""},{"nctId":"NCT02314117","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01-20","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":645},{"nctId":"NCT01774786","phase":"PHASE3","title":"A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-06-10","conditions":"Gastric Cancer","enrollment":780},{"nctId":"NCT01133678","phase":"PHASE2","title":"Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2010-05-04","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT03881111","phase":"PHASE3","title":"First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-21","conditions":"Esophageal Neoplasms","enrollment":""},{"nctId":"NCT04146402","phase":"PHASE3","title":"SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-12-31","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":330},{"nctId":"NCT03342352","phase":"PHASE3","title":"Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2017-12-15","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT03855384","phase":"PHASE3","title":"Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-06-11","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":334},{"nctId":"NCT01836029","phase":"PHASE2","title":"Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-10-14","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":195},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT00548548","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-09","conditions":"Adenocarcinoma","enrollment":774},{"nctId":"NCT00887822","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Gastric Cancer","enrollment":202},{"nctId":"NCT01123473","phase":"PHASE2","title":"Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2010-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer","enrollment":29},{"nctId":"NCT02137343","phase":"PHASE3","title":"A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-07","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT01697072","phase":"PHASE3","title":"First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-10","conditions":"Gastric Cancer","enrollment":609},{"nctId":"NCT01232374","phase":"PHASE2","title":"Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2010-09","conditions":"Squamous Cell Carcinoma","enrollment":144},{"nctId":"NCT01829178","phase":"PHASE2, PHASE3","title":"Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2013-08","conditions":"Upper GI Cancer, Cisplatin Adverse Reaction","enrollment":30},{"nctId":"NCT00583674","phase":"PHASE2","title":"Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-12","conditions":"Gastrointestinal Cancer","enrollment":171},{"nctId":"NCT00719550","phase":"PHASE1, PHASE2","title":"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-02","conditions":"Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo+ Fluorouracil+Cisplatin","genericName":"Placebo+ Fluorouracil+Cisplatin","companyName":"CStone Pharmaceuticals","companyId":"cstone-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses fluorouracil and cisplatin chemotherapy agents to inhibit DNA synthesis and induce cancer cell death, with placebo as a control arm in the trial design. Used for Gastric or gastroesophageal junction cancer (likely indication based on CStone pipeline).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}